Areas of interest (AOI) & competitive research grants

We are currently accepting concepts for the following therapeutic areas. BMS periodically opens RFP Cycles across different therapeutic areas and the pre-concept submission periods will be posted below when available. We strongly encourage all applicants to begin the online application process early to allow adequate time for completion. For a submission to qualify for review, all information including any required uploads must be submitted through the application form prior to the specified end dates for the RFP Cycle.

Therapeutic Area and / or Compound AOIs Posted on BMS.com Pre-Concept Submission Period
Start Date End date
Neuropsychiatry - KarXT (Xanomeline/trospium) Sept 27, 2024 Oct 28, 2024 Jan 3, 2025


KarXT ISR Areas of Interest – RFP #1 2024

 

  • Investigation of disease states where the pharmacology of KarXT matches with the hypothesized underlying biology of psychiatric illnesses.

  • Understanding the impact of KarXT on the following in patients with SCZ:
    • Overall functioning​
    • Cognitive functioning​
    • Predominant negative symptoms​
    • Additional measures of response (e.g., patient satisfaction, other Patient-Reported Outcomes)​
       
  • Additional areas of interest for the approved indication (schizophrenia)
    • KarXT in Early Psychosis​
    • Real-world use and efficacy/safety (Clinical, HEOR or both)​
    • Burden of disease​
    • Costs related to the disease and its treatments​
    • The safety and efficacy of switching to KarXT from other antipsychotics ​
    • Novel outcomes related to treatment with KarXT​
    • Pharmacogenetic predictors of KarXT response​
    • Use of AI to determine predictors of response (existing or new data)​
    • Treatment-resistant schizophrenia or treatment-experienced patients​
    • Efficacy in patients with schizophrenia and medical or psychiatric comorbidities (eg., substance-use disorder)​
    • Imaging studies to further the understanding of M1/M4 muscarinic receptors in the disease state or MOA of KarXT​
       
  • Non-clinical studies furthering the understanding of the role of KarXT in schizophrenia ​
     

Out of Scope

  • Indications and/or patient populations where KarXT has been or is being evaluated
    • Relapse prevention in patients with schizophrenia​
    • Adolescent schizophrenia​
    • Autism spectrum disorder​
    • Bipolar 1 disorder​
    • Alzheimer’s disorder (psychosis, agitation)​
       
  • Populations requiring treatment with centrally acting anticholinergic agents
  • Patients with medical conditions that are not compatible with KarXT use (eg, urinary retention, gastric retention, narrow-angle glaucoma)

Please note that during an open RFP submission window, clicking on a link to submit your research idea will take you to the FastTrack Investigator Portal and you will receive a message that you are leaving BMS.com. This is part of the normal process.

  • If you are a potential investigator who is interested in seeking support to conduct independent research involving  Nivolumab  in Japan, Taiwan, or Korea, click here
  • If you are a potential investigator who is interested in seeking support for independent research using Apixaban, click here.
  • If you are a potential investigator who is interested in seeking support for non-clinical research using a BMS product, click here
  • If you are a potential investigator who is interested in seeking support for independent research using one of our early pipeline assets, click here

Please click on the product name to see the Full U.S. Prescribing Information for ELIQUIS®, EMPLICITI, NULOJIX®, OPDIVO®, ORENCIA®, SPRYCEL®, YERVOY®, including Boxed WARNINGS for ELIQUIS®, NULOJIX®, and Boxed WARNING for YERVOY® regarding immune-mediated adverse reactions.

Begin a new application